key: cord-0820456-34uorjgw
authors: Johnson, K.; Khayyat-Kholghi, M.; Johnson, B.; Tereshchenko, L. G.
title: The Association Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Number of Covid-19 Confirmed Cases and Deaths in the United States: Geospatial Study
date: 2020-06-01
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2020.05.31.20118802
sha: 33a4834dcf039320ff28debbd0f204315a6b26b1
doc_id: 820456
cord_uid: 34uorjgw

Background: The novel coronavirus SARS-Cov2 uses the angiotensin-converting enzyme 2 (ACE2) receptor as an entry point to the cell. Cardiovascular disease (CVD) is a risk factor for the novel coronavirus disease (Covid-19) with poor outcomes. We hypothesized that the rate of ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) use is associated with the rate of Covid-19 confirmed cases and deaths. Methods: We conducted a geospatial study using publicly available county-level data. The Medicare ACEIs and ARBs prescription rate was exposure. The Covid-19 confirmed case and death rates were outcomes. Spatial autoregression models were adjusted for the percentage of Black residents, children, residents with at least some college degree, median household income, air quality index, CVD hospitalization rate in Medicare beneficiaries, and CVD death rate in a total county population. Results: The ACEI use had no effect on Covid-19 confirmed case rate. An average ACEIs use (compared to no-use) was associated with a higher Covid-19 death rate by 1.1 (95%CI 0.4-1.8)%. If the use of ACEIs increases by 0.5% for all counties, the Covid-19 death rate will drop by 0.4% to 0.7(95%CI 0.3-1.1)%; P<0.0001. An average ARBs use (compared to no-use) was associated with a higher Covid-19 confirmed case rate (by 4.2; 95%CI 4.1-4.3 %) and death rate (by 1.1; 95%CI 0.7-1.5 %). Each percent increase in ARBs use was associated with an increase in confirmed case rate by 0.2(0.03-0.4)% and death rate by 0.14(0.08-0.21)%. Conclusions: ARBs, but not ACEIs use rate, is associated with Covid-19 confirmed case rate.

The novel coronavirus disease 2019 (Covid-19) caused by SARS-Cov2 virus was named a pandemic officially by the World Health Organization on March 11 th , 2020. 1, 2 It has been shown that SARS-Cov2 uses the angiotensin-converting enzyme 2 (ACE2) receptor as an entry point into a cell [2] [3] [4] .

With the ACE2 receptor acting as a binding site for SARS-Cov2, the Renin-Angiotensin-Aldosterone System (RAAS), and the medications affecting it become important points of discussion. 1, [5] [6] [7] [8] Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two common classes of medications widely used in patients with hypertension, diabetes, and cardiovascular disease (CVD), a latent or manifest left ventricular dysfunction. Hypertension, diabetes, and CVD emerged as risk factors for severe Covid-19 cases and deaths. [9] [10] [11] Previous experiments showed that ACE2 expression is associated with susceptibility to SARS-Cov infection. 12 Notably, available clinical studies consider ACEIs and ARBs together 5, 8 . However, the effects of ACEI and ARBs on ACE2 levels and activity are different. 8 Experimental studies showed that there is no direct effect of ACEIs on ACE2 activity. 13 While there is strong evidence that ARBs increase ACE2 expression [14] [15] [16] [17] [18] [19] and augment ACE2 activity 20,21-23 , only Ferrario et al 24 showed that ACEIs increase ACE2 expression, whereas other studies showed that ACEIs decrease 25 or did not change levels and activity of ACE2 in tissue. 20, 26 The consensus is reached by all international cardiac societies about the importance of the continuation of ACEIs and ARBs use in Covid-19 pandemic. 5 However, it remains unknown whether clinically indicated use of ACEIs and ARBs improve or worsen infectivity or the course of Covid-19, and whether there are differences between ACEIs and ARBs. dataset included the total number of prescriptions that were dispensed (total day supply), which include original prescriptions and any refills, and, therefore, reflects ACEIs and ARBs usage.

The Medicare dataset only includes city and state information and not county information. In order to map the Medicare prescription data to their corresponding FIPS Code, we used the Google Geocoding API. 29 We then loaded the Medicare data and geocoded data into the SQLite database to produce the final datasets with prescription counts per county. Prescriptions from county-equivalents (independent cities) were manually matched with their corresponding FIPS code. Medicare prescriptions with misspelled cities or prescriptions that lacked valid city and state descriptions, if unable to be assigned, were excluded. Excluded prescriptions accounted for <0.01% of the data.

We calculated a drug class use rate as a sum of total day supply in a county for all drugs comprising a particular class (Table 1) , normalized by the total county population estimate. We used the US Census Annual Resident Population Estimates for July 1 st , 2019.

We imported the raw COVID-19 data from the Johns Hopkins GitHub repository. 30 The number of confirmed COVID-19 cases and deaths in each county as reported for May 12 th , 2020 was divided by the total population in each county (2019 county population estimate) and multiplied by 100,000 to convert to cases and deaths per 100,000 population. The primary outcome was the total number of confirmed Covid-19 cases in each county per 100,000 population, as reported for May 12 th , 2020. The secondary outcome was the total number of Covid-19 deaths in each county per 100,000 population, as reported for May 12 th , 2020.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. . https://doi.org/10.1101/2020.05.31.20118802 doi: medRxiv preprint

We used the US Census County Population Estimates, released in March 2020, and included reported deaths and births in period July 1 st , 2018 to June 30 th , 2019. 31 Due to known negative impact of Covid-19 on the population of nursing homes and prisons/jails, we included July 1 st , 2019 Group Quarters total population estimate. Group Quarters Facilities include correctional facilities for adults, nursing homes, college/university student housing, military quarters, and group homes. Group Quarters data was gathered from an estimated 20,000 randomly selected facilities. Data was then collected through resident interviews of these selected facilities using the American Community Survey conducted by the US Census Bureau. 32 The total 2019 county population estimate 31 normalized all demographic characteristics.

To characterize socioeconomic characteristics, we used the 2018 median household income expressed as a percent of the state total, and percent of the total population in poverty, as reported by the Economic Research Service of the US Department of Agriculture. 33 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. To characterize the use of cardiovascular medications, we calculated the rate of cardiovascular medications use, which included original prescriptions and any refills (total day supply), as reported in the 2017 CMS Part D Medicare Prescriber Public Use File. 28 We considered the total day supply data for 20 medication groups (Table 1) : ACEI, ARB, betablockers, alpha-and-beta-blockers, alpha-blockers, class I, III, and V antiarrhythmic medications, dihydropyridine, and non-dihydropyridine calcium channel blockers, aldosterone antagonists, central acting antihypertensive medications, vasodilators, diuretics, lipid-lowering drugs, insulins, and oral hypoglycemic agents, anticoagulants and antiplatelet medications. We normalized the cardiovascular medications day supply for each county by the 2019 county population estimate. 31

Data are summarized as mean ± standard deviation or as the median and interquartile range (IQR) if non-normally distributed. A paired t-test was used to compare an average rate of ACEIs and ARBs use.

As Covid-19 is a contagious disease, incidence and mortality in neighboring counties are spatially correlated. Therefore, we used spatial autoregression model 36 that allows modeling the spatial dependence among the outcomes, covariates, and among unobserved errors. 37 The spatial All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. . https://doi.org/10.1101/2020.05.31.20118802 doi: medRxiv preprint autoregression model used the generalized spatial two-stage (method-of-moment), least-squares estimator. 38 The model included spatial lags of the outcome variable, spatial lags of covariates, and spatially autoregressive errors. The lag operator was a spatial weighting (inverse-distance) matrix, which summarized spatial relationships between counties, based on the distance between county centroids. Weighting matrix was scaled so that its largest eigenvalue is 1, which guarantees nonsingularity in the model estimation. We constructed cross-sectional spatial autoregressive models. The estimator treated the errors as heteroskedastic, thus relaxing the assumption that errors represent identically distributed disturbance.

We conducted the Moran test to determine whether exposure, outcome and covariate variables are spatially dependent.

First, we constructed unadjusted spatial autoregression models, to investigate a geospatial association of the county population characteristics with the ACEIs and ARBs use rate, calculated as follows:

ACEIs use rate = ln (total ACEIs day supply/county population).

ARBs use rate = ln (total ARBs day supply/county population).

Each model included spatial lags of the outcome variable (ACEIs or ARBs use rate, one-byone), spatial lags of the testes predictor variable (demographic, socioeconomic, and CVD prevalence characteristics, one-by-one), and spatially autoregressive errors (reflecting unobserved factors).

Next, we constructed unadjusted spatial autoregression models, to evaluate a geospatial association of the county population characteristics with the rate of Covid-19 confirmed cases and deaths. To normalize the distribution of the outcome variables, and to improve the interpretability of models, we transformed outcome variables as follows: All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. Each model included spatial lags of the outcome variable (Covid-19 confirmed case rate and death rate, one-by-one), spatial lags of the tested predictor variable (demographic and socioeconomic characteristics, cardiovascular risk factors and CVD prevalence, and the rate of ACEIs or ARBs use, one-by-one), and spatially autoregressive errors (unobserved impacts).

Finally, we constructed adjusted spatial autoregression models to answer the main study question: whether there is an independent association of ACEIs and ARBs use rate with Covid-19 confirmed case and death rate. The selection of covariates for adjustment was guided by observed in this study confounders (covariates that statistically significantly associated with both predictor and outcomes variables) and model fit. We were striving to obtain the highest R 2 value and χ 2 statistic (Wald test of spatial terms). Our final models explained at least 30% of the variability in each outcome (R 2 value >0.3). We adjusted for demographic and socioeconomic characteristics of a county population (percentage of Black non-Hispanic county residents, percentage of a county residents younger than 18 years of age, percentage of residents with at least some college degree, median household income as a percent of state total), air quality index, as well as CDC-reported CVD hospitalization rate in Medicare beneficiaries, and CVD death rate in a total county population. Each model included spatial lags of the outcome variable (Covid-19 incidence and mortality, one-by-one), spatial lags of the tested predictor variable (rate of ACEIs or ARBs usage, one-by-one), spatial lags of the selected (listed above) 7 covariates (altogether) and spatially autoregressive errors (unobserved influences).

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. . https://doi.org/10.1101/2020.05.31.20118802 doi: medRxiv preprint

Cross-sectional geospatial analysis is susceptible to reverse causality bias. It is welldocumented that patients with CVD and cardiovascular risk factors (hypertension, diabetes) have a higher rate of Covid-19 confirmed cases and deaths. 5 The rate of ACEIs and ARBs use indirectly indicates CVD prevalence and severity. While we adjusted our models for the broad range of confounders, including CVD mortality in a total county population, and CVD hospitalization rate among Medicare beneficiaries, reverse causality remained of concern. To assess the possibility and extend of reverse causality bias, we constructed described above spatial autoregression models for the rate of use of other cardiovascular medications, for each class of drugs separately, one-by-one.

We analyzed the data of 3,141 counties and county-equivalents in the 50 states and the District of Columbia. ACEIs were the most ubiquitous medications, surpassed only by lipidlowering drug use (Table 1) . Average county characteristics are reported in Table 2 . Figure 1 shows the ACEIs and ARBs total day supply rates across the US. On average, the total day supply rate was higher for ACEIs than for ARBs (10.3±6.5 vs. 6.0±4.6 days; P<0.0001), as shown in Figure 1C . The Moran test indicated that the rates of ACEIs and ARBs use were spatially dependent (P<0.0001).

In unadjusted spatial autoregression analysis (Table 3) , as expected, CVD prevalence, general demographic characteristics, uninsured rate, and air quality were associated with the use of both ACEIs and ARBs. A higher percentage of adults above 65 y of age was associated with All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. . https://doi.org/10.1101/2020.05.31.20118802 doi: medRxiv preprint higher use of ACEIs, but not ARBs. A higher percentage of Asians was associated with the use of ARBs, but not ACEIs.

Covid-19 confirmed case and death rate ( Figure 2 ) had similar geographic distribution. As of May 12 th , 2020, in an average county, there were median 84.8 (IQR 34.4 -208.6) confirmed cases and median 0.35 (IQR 0 -7.6) deaths per 100,000 population.

In unadjusted spatial autoregression analysis (Table 4) , higher CVD and HF hospitalization rate among Medicare beneficiaries, a higher percentage of Blacks, Hispanics, Asians, and Pacific Islanders, a greater proportion of children (age < 18y) and residents admitting excessive drinking, a higher percentage of households with high housing costs, and worse air quality were associated with a higher rate of confirmed Covid-19 cases. In contrast, a larger proportion of county residents admitting physical inactivity, a greater percentage of adults above 65 years of age and non-Hispanic Whites, greater uninsured rate, and higher CVD mortality across all ages were associated with a lower rate of confirmed Covid-19 cases ( Table 4 ). The same factors that affected Covid-19 confirmed case rate also affected Covid-19 death rate, but the strength of the impact on mortality was lesser. As expected, we observed significant indirect (spillover) effects of socioeconomic factors coming from neighboring counties on confirmed Covid-19 case and death rate to a given county.

In unadjusted analysis, as expected, both ACEI and ARB use rate had a direct and indirect impact on confirmed Covid-19 case and death rate (Table 5) .

However, the association of ACEI use with Covid-19 was fully explained by confounders (Table 5 ). In adjusted analyses, the ACEI use rate had no effect on Covid-19 confirmed case rate, All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. . https://doi.org/10.1101/2020.05.31.20118802 doi: medRxiv preprint as demonstrated by the marginsplot ( Figure 3A ). There was no significant observed averaged effect (the observed averaged marginal effect was +4.4%; 95%CI from -16.5 to 41.6%), and no effect from a change of ACEIs use rate in all counties on Covid-19 confirmed case rate, as illustrated by the perfectly flat line ( Figure 3A ). There was a significant observed marginal effect on Covid-19 mortality (1.08%; 95%CI 0.35-1.81%), which suggested that an average ACEIs use rate (as compared to no ACEI use) was associated with higher Covid-19 mortality, by 1.1%. If the use of ACEIs increases by 0.5% for all counties, Covid-19 mortality will drop by 0.36%, from 1.08(95%CI 0.35-1.81)% to 0.72(95%CI 0.34-1.10)%; P<0.0001 ( Figure 3B ).

Nevertheless, after adjustment for demographic and socioeconomic characteristics, air quality index, and CVD prevalence and mortality, the rate of ARBs use remained significantly associated with Covid-19 outcomes (Table 5) . On average, an increase in ARB use rate in a given county by 1% was associated with a 0.20 % increase in Covid-19 confirmed cases and a 0.14% increase in Covid-19 deaths in that county (direct, county-own effect). There was a significant observed effect of ARBs use. The observed averaged marginal effect was 4.21 (95%CI 4.13-4.29) % on Covid-19 confirmed case rate, which suggested that an average ARBs use (as compared to no use) was associated with a significantly higher number of confirmed Covid-19 cases ( Figure 3C ). There was a non-significant trend towards a lower rate of confirmed cases with a higher rate of ARBs use. If the use of ARBs increases by 0.5% for all counties, Covid-19 confirmed cases nonsignificantly decline by 0.68% ( Figure 3C ). There was also a significant observed marginal effect on Covid-19 mortality, which suggested that an average ARBs use (as compared to no ARB use) was associated with higher Covid-19 mortality by 1.06% (95%CI 0.68-1.45%). If the use of ARBs increases by 0.5% for all counties, Covid-19 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. . https://doi.org/10.1101/2020.05.31.20118802 doi: medRxiv preprint mortality will nonsignificantly decrease by 0.24% from 1.06(95%CI 0.68-1.45)% to 0.82(95%CI -0.04 to 1.67)%; P=0.062 ( Figure 3D ).

Of note, adjustment fully explained the indirect (spillover) effect of ACEIs and ARBs use rate coming from all neighboring counties on Covid-19 confirmed case and death rate to a given county, while all models confirmed strong spatial dependence (Wald test of spatial terms for all models P<0.00001).

In unadjusted analysis, the use of cardiovascular medications reflects CVD prevalence. As expected, the use of nearly all types of cardiovascular medications was associated with Covid-19 confirmed case rate (Supplemental Table 1 ), with few exceptions. The use of antiarrhythmic drugs (class I. III, and V), and vasodilators was associated with a lower rate of confirmed Covid-19 cases. The use of vasodilators was also associated with a lower Covid-19 death rate. Overall, an association of medications use rate with Covid-19 death rate was similar to the association of medications use rate with Covid-19 confirmed case rate but had a smaller effect size.

In adjusted analysis (Supplemental Table 2 ), the rate of use of the vast majority of cardiovascular medications had no association with Covid-19 confirmed case and death rate.

This finding supports the validity of the primary study analyses.

There are two main findings in this study. First, we confirmed that the rate of ACEIs use does not impact Covid-19 confirmed case rate. Moreover, an increase in the ACEIs use rate is associated with a nearly equal (~ 1:1) drop in the Covid-19 death rate. Our results highlight the safety and indicate possible benefits of ACEIs use for patients with clinical indications for ACEI All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. 39, 40 Second, we observed that ARBs use associated with a slightly higher rate of Covid-19 confirmed case and death rate. After adjustment for demographic and socioeconomic confounders and CVD prevalence, an increase in ARBs use by 1% was associated with a 0.20 % increase in Covid-19 confirmed cases and a 0.14% increase in Covid-19 deaths. This finding suggests that long-term use of ARBs, due to known ACE2 upregulation, may facilitate SARS-CoV-2 entry and increase infectivity. ACEIs and ARBs are frequently prescribed interchangeably for the same clinical indications. Cluster-randomized controlled trial is warranted to answer the question of whether the replacement of ARBs by ACEIs may reduce Covid-19 confirmed case rate. Importantly, in this observational geospatial study, residual confounding and reverse causality bias cannot be completely ruled out. The use of ARBs may indicate a subgroup of CVD patients who are especially vulnerable to the virus. In such a case, the use of ARBs is not a cause, but a marker of risk. Therefore, it is essential to reinforce effective Covid-19 prevention strategies in patients taking ARBs, to avoid virus exposure.

There is strong evidence that the entry of the SARS-CoV-2 virus into the host cell depends on the SARS-CoV receptor ACE2. 41 ACE2 is a type I integral membrane glycoprotein expressed mainly in the respiratory tract, heart, kidneys, and gastrointestinal tract. 42 ACE2 tissue expression facilitates the virus entry in target cells. 12 Clinical indications for ACEIs and ARBs are similar, and in many clinical studies, these two classes of drugs considered together under the common name "RAAS inhibitors." However, the effects of ACEI and ARBs on ACE2 levels and activity are different. 8 Experimental studies All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. Our findings support the hypothesis that long-term use of ARBs, but not ACEIs may facilitate SARS-CoV-2 entry and increase infectivity. Several recent studies 39, 40 reported findings pointed to the same direction.

As in any observational study, we have to emphasize that reverse causality bias should be considered. Several unmeasured confounders could be responsible for our findings. First, ARBs are indicated to patients who are intolerant to ACEIs, usually because of bradykinin-mediated cough. Second, both ACEIs and ARBs can be used together in patients with advanced HF, and thus indicate a high-risk patient population. For those patient categories, switching from ARBs to ACEIs is not an option. Nevertheless, regardless of whether ARBs indeed increase infectivity or simply indicate a high-risk patient population, it would be wise to reinforce effective Covid-19 prevention strategies, to minimize the risks of exposure to the virus.

Our findings support the notion of ACEIs and ARBs playing a "double-edged sword" 6, 7, 43 role. The impact of ARBs on Covid-19 death rate was smaller than on Covid-19 confirmed case rate, suggesting no adverse effect on Covid-19 disease severity. Moreover, we observed a nonsignificant decrease in Covid-19 death rate associated with an increase in ARBs use rate.

Notably, we showed that if ACEIs use rate increases by 1% for all counties, Covid-19 death rate will drop by ~0.8%, demonstrating nearly 1:1 relationships. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. . https://doi.org/10.1101/2020.05.31.20118802 doi: medRxiv preprint By degrading angiotensin II, ACE2 reduces its effect on the RAAS system. 1 It has been shown 44 that ARBs may have a greater potential 45 to block the RAAS system 46 than ACEIs, and the proposed mechanism is due to the fact that about 40% of the angiotensin II is formed via non-ACE pathways. ARBs also block the excessive angiotensin-mediated AT1R activation 47 caused by the viral infection and exert anti-inflammatory effects. 48 Our findings support current recommendations of continued use of ACEIs and ARBs in Covid-19 patients. 5

Although the Medicare Part D Prescriber Public Use File has a wealth of information, the dataset has several limitations. The data may not be representative of a physician's entire practice or all of Medicare as it only includes information on beneficiaries enrolled in the Medicare Part D prescription drug program (approximately two-thirds of all Medicare beneficiaries). Besides, available data were for the year 2017 and did not reflect the most recent use of medications in 2020. Nevertheless, we measured exposure before the outcome, which is essential for the interpretation of the study findings. Furthermore, we did not adjust for adherence to medications. Nevertheless, a recent geospatial study of ACEI/ARB adherence 49 showed a relatively consistent geographic distribution of ACEI/ARB adherence across the US.

An observational cross-sectional geospatial study is susceptible to reverse causality bias. To address this limitation, we performed a rigorous analysis of all other classes of cardiovascular medications. The results of sensitivity analyses were logically coherent and consistent with the main study results. Finally, unobserved confounding was likely present in this observational study. The most apparent missing data included the rate of Covid-19 testing. Therefore, observed effect sizes have to be interpreted with caution. However, unobserved confounding would not affect a relative comparison of ACEIs and ARBs. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. . https://doi.org/10.1101/2020.05.31.20118802 doi: medRxiv preprint

Authors acknowledge numerous scientists and institutions that provided open data.

This research was supported in part by the National Institute of Health HL118277 (LGT).

None.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. . https://doi.org/10.1101/2020.05.31.20118802 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. Alpha-Glucosidase Inhibitors Miglitol Acarbose 9.0(5.9-12.1) All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 1, 2020. . https://doi.org/10.1101/2020.05.31.20118802 doi: medRxiv preprint for the percentage of Black non-Hispanic county residents, percentage of a county residents younger than 18 years of age, percentage of residents with at least some college degree, median household income as a percent of the state total, air quality index, CVD hospitalization rate in Medicare beneficiaries, and CVD death rate in a total county population.

Clinical Implications of SARS-Cov2 Interaction with Renin Angiotensin System

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

Current perspectives on Coronavirus 2019 (COVID-19) and cardiovascular disease: A white paper by the JAHA editors

On Two-Step Estimation of a Spatial Autoregressive Model with Autoregressive Disturbances and Endogenous Regressors

Asymptotic Distributions of Quasi-Maximum Likelihood Estimators for Spatial Autoregressive Models

Specification and estimation of spatial autoregressive models with autoregressive and heteroskedastic disturbances

Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study